← All trials
NCT06388733
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 19, 2024
- Primary completion
- Dec 31, 2027
- Completion date
- Mar 31, 2028
- First posted
- Apr 29, 2024
- Last posted
- Jun 24, 2024
- Enrollment
- 450
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ivy Brain Tumor CenterLead sponsor
- Ivy Brain Tumor CenterOfficial
- GlaxoSmithKlineCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.